IDH1 and glioblastoma: This group of tumors had intermediate prognosis as IDH1/2 mutated tumors lacking 1p/19q codeletion (Group II and III), indicating that merely wild-type IDH1/2 status may not be invariably associated with poor clinical outcome and additional glioblastoma-like molecular alterations are required to prognosticate a particularly unfavorable survival [38].